Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Cercek on the Need for Treatment Options in KRAS-Mutated mCRC

February 11th 2020

Andrea Cercek, MD, discusses the need for treatment options in KRAS-mutated metastatic colorectal cancer (mCRC).

Dr. Cercek on the Importance of Molecular Testing in CRC

February 8th 2020

Andrea Cercek, MD, discusses the importance of molecular testing in colorectal cancer.

Novel Therapeutic Targets and Combinations in mCRC

February 8th 2020

MCRC: Future Directions for Molecular-Driven Treatment

February 8th 2020

Immunotherapy for MSI-High/dMMR mCRC

February 8th 2020

Evolution of MSI Testing for mCRC

February 8th 2020

Treatment Strategies for HER2-Amplified mCRC

February 8th 2020

Optimal Therapy for BRAF-Mutated mCRC

February 8th 2020

Impact of BRAF Mutations on Metastatic Colorectal Cancer

February 8th 2020

MCRC: Sequencing Based on RAS Status and Tumor Sidedness

February 8th 2020

MCRC: Molecular Testing

February 8th 2020

Importance of Tumor Sidedness in mCRC

February 8th 2020

Predictive Markers for mCRC

February 8th 2020

Molecular Testing for Metastatic CRC in 2020

February 8th 2020

Dr. Weinberg on the Role of Cetuximab in Metastatic CRC

February 7th 2020

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Dr. Putcha on the Use of Blood-Based Screening Assays in CRC

February 5th 2020

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC

January 27th 2020

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS

January 26th 2020

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in BRAF+ mCRC

January 25th 2020

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.